Key Market Insights

• The North America region dominated the global albumin market market with the largest revenue share of 40% in 2024.
• Based on product type, the human serum albumin segment dominated the albumin industry in 2024.
• Based on application, the drug delivery and vaccine stabilisation segment has emerged as the most dynamic application segment.
• Based on distribution channel, the hospital pharmacies segment dominate the distribution landscape for albumin.
• Based on end-user, the hospitals and clinics form segment are the primary end-user group in the market.

Albumin Market Trend

Recombinant albumin gains ground as safer, scalable alternative to plasma-derived sources

The albumin market is undergoing a notable transformation as biotechnology companies and pharmaceutical manufacturers shift toward recombinant human serum albumin (rHSA) to address concerns around plasma supply limitations, pathogen safety, and regulatory compliance. This reflects a broader move within the life sciences industry to adopt more consistent, ethically sourced, and scalable inputs, especially for vaccines, biologics, and cell-based therapies.

• For instance, in June 2024, Sartorius announced that its recombinant albumin, developed through its acquisition of Albumedix, played a key role in stabilising the world’s first FDA-approved chikungunya vaccine, IXCHIQ®. The rHSA was used as a formulation stabiliser, supporting cold-chain storage without compromising the vaccine’s potency.

List of key players in Albumin Market

1. CSL Behring
2. Grifols S.A.
3. Takeda Pharmaceutical Company Limited
4. Octapharma AG
5. Merck KGaA
6. Baxter International Inc.
7. Kedrion Biopharma Inc.
8. HiMedia Laboratories Pvt. Ltd.
9. Thermo Fisher Scientific Inc.
10. Albumedix Ltd. (a part of Sartorius AG)
11. Recombinant Technologies Inc.
12. Mitsubishi Tanabe Pharma Corporation
13. InVitria (a division of Ventria Bioscience)